公开(公告)号：US20140315804A1

公开(公告)日：2014-10-23

申请号：US14210354

申请日：2014-03-13

Applicant: GENZYME CORPORATION

Inventor： Peter PECHAN ,  Jeffery ARDINGER ,  Hillard RUBIN ,  Samuel WADSWORTH ,  Abraham SCARIA

IPC: C07K14/71

CPC classification number: C07K14/71 ,  A61K38/00 ,  C07K2319/30 ,  C07K2319/70 ,  C12N2510/02 ,  C12N2750/14143

Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.

Abstract translation: 本发明提供了包含PDGF和VEGF结合部分的融合蛋白，以及编码融合蛋白的重组病毒颗粒。 还提供了包含融合蛋白和病毒颗粒的组合物以及其使用方法。

公开(公告)号：US20220340883A1

公开(公告)日：2022-10-27

申请号：US17686245

申请日：2022-03-03

Applicant: Genzyme Corporation

Inventor： Peter PECHAN ,  Jeffery ARDINGER ,  Abraham SCARIA ,  Samuel WADSWORTH

IPC: C12N7/00

Abstract: The use of iNOS inhibitors, including aurintricarboxylic acid, dexamethasone and valproic acid, to increase the yield of a variety of viruses in culture, including recombinant herpesviruses is described.

公开(公告)号：US20220064262A1

公开(公告)日：2022-03-03

申请号：US17367027

申请日：2021-07-02

Applicant: Genzyme Corporation

Inventor： Peter PECHAN ,  Jeffery ARDINGER ,  Hillard RUBIN ,  Samuel WADSWORTH ,  Abraham SCARIA

IPC: C07K14/71 ,  A61K38/00

Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.

公开(公告)号：US20170342127A1

公开(公告)日：2017-11-30

申请号：US15471725

申请日：2017-03-28

Applicant: Genzyme Corporation

Inventor： Peter PECHAN ,  Jeffery ARDINGER ,  Hillard RUBIN ,  Samuel WADSWORTH ,  Abraham SCARIA

IPC: C07K14/71 ,  A61K38/00

CPC classification number: C07K14/71 ,  A61K38/00 ,  C07K2319/30 ,  C07K2319/70 ,  C12N2510/02 ,  C12N2750/14143

Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.

公开(公告)号：US20170304465A1

公开(公告)日：2017-10-26

申请号：US15511595

申请日：2015-09-16

Applicant: Genzyme Corporation

Inventor： Peter PECHAN ,  Abraham SCARIA ,  Jeffery ARDINGER

IPC: A61K48/00 ,  A61K38/17 ,  A61K9/00 ,  C07K14/47 ,  C12N7/00 ,  C12N15/113 ,  C12N15/86

Abstract: Provided herein are methods for treating myocilin (MYOC) glaucoma using adeno-associated viral (AAV) vectors. In some aspects, the AAV vectors encode R-spondin 1 (RSPO1), R-spondin 2 (RSPO2), R-spondin 3 (RSPO3) or R-spondin 4 (RSPO4) and/or RNAi that targets myocilin (MYOC). In one aspect, viral particles are administered to the eye of a human subject. Viral particles encoding RSPO1, RSPO2, RSPO3 and/or RSPO4 and/or MYOC RNAi are contemplated. In some aspects, variant AAV2 particles that transduce the trabecular meshwork are provided.